Friday, September 23, 2016

Puma Biotechnology Announces FDA Acceptance of NDA for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

… with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant … patients with early stage HER2-positive breast cancer, there remains an unmet clinical … 41 countries with early-stage HER2-positive breast cancer who had undergone surgery and …

No comments:

Post a Comment